OPTIMIZED BIO-SYNCHRONOUS BIOACTIVE AGENT DELIVERY SYSTEM
Optimized bio-synchronous drug delivery begins with establishing a bio-synchronous treatment protocol that incorporates individual temporal and innate biological characteristics into a pharmacological treatment plan. The bio-synchronous treatment protocol is thereafter initiated using bioactive agent delivery device. Bio-synchronous drug delivery includes continual collection of patient data such as physical, psychological, temporal and environmental characteristics. This data is analyzed so to not only determine an initial treatment protocol but to also determining whether modification to the ongoing bio-synchronous treatment protocol is required. And, responsive to determining a modification is required the system modifies the bio-synchronous treatment protocol and use of delivery device. These modifications and treatment protocols can include reactive and proactive psychological support supplied to the patient in a variety of formats.
1 . A treatment system comprising:
a bio-synchronous delivery device configured to administer a bioactive agent to a patient based on a bio-synchronous treatment protocol;
a user interface adapted to receive patient data; and
an analysis module adapted to receive patient data from the user interface and to provide psychological support to the patient based on the patient data.
2 . The treatment system of claim 1 wherein a smart phone provides the user interface.
3 . The treatment system of claim 1 wherein the bio-synchronous delivery device comprises the user interface.
4 . The treatment system of claim 1 wherein the bio-synchronous delivery device comprises a physiological sensor adapted to collect additional patient data.
5 . The treatment system of claim 1 wherein patient data includes patient emotional state data.
6 . The treatment system of claim 5 wherein patient emotional state data includes cravings.
7 . The treatment system of claim 5 wherein patient emotional state data includes anxiety.
8 . The treatment system of claim 1 wherein the psychological support includes emotional support.
9 . The treatment system of claim 1 wherein the analysis module is further adapted to provide emotional support by a text message, supportive tip, vibrating tone, e-mail, call, or voicemail message.
10 . The treatment system of claim 1 wherein the analysis module is further adapted to modify the bio-synchronous drug delivery protocol.
11 . The treatment system of claim 1 wherein patient data includes information about compliance with the bio-synchronous drug delivery protocol.
12 . The treatment system of claim 11 wherein information about compliance with the bio-synchronous drug delivery protocol includes contact of the bio-synchronous delivery device with the patient's skin.
13 . The treatment system of claim 11 wherein information about compliance with the bio-synchronous drug delivery protocol includes one or more removal of the bio-synchronous delivery device, missing a treatment in the bio-synchronous treatment protocol, or interruption of the bio-synchronous treatment protocol.
14 . The treatment system of claim 11 wherein information about compliance with the bio-synchronous drug delivery protocol includes time of administration of the bioactive agent, a dosage amount of the bioactive agent, and a time at which dosing ceased.
15 . The treatment system of claim 1 wherein the bioactive agent is chosen from the group consisting of alprazolam, apomorphine, azelastine, buprenorphine, bupropion, clonidine, enalpril, estradiol, ethinyl estradiol, fentanyl, granisetron, insulin, lidocaine, memantine, methylphenidate, methamphetamine, nitroglycerine, nicotine, norethisterone acetate (NETA), norelgestromine, oxybutynin, pergolide, phenteramine, pramipexole, ramipril, ropinirole, rotigotine, scopolamine, selegiline, tecrine, testosterone, timolol and tolterodine.